Atea Pharmaceuticals, Inc. (AVIR) vs Eikon Therapeutics, Inc. Common Stock (EIKN)

A side-by-side comparison of Atea Pharmaceuticals, Inc. and Eikon Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Atea Pharmaceuticals, Inc. logo
AVIR
Atea Pharmaceuticals, Inc.
$404M
$5.05HealthcareDelayed quote: Oct 6, 2026, 1:59 PM EDT
Eikon Therapeutics, Inc. Common Stock logo
EIKN
Eikon Therapeutics, Inc. Common Stock
$409M
$7.55HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT

Total return — AVIR vs EIKN

growth of $100 · dividends reinvested · last 1y
AVIR +25.1% (+25.1%/yr)EIKN -49.7% (-49.7%/yr)AVIR compounded faster over this window
6080100120140Start $100$125$50
AVIR EIKN

AVIR vs EIKN: by the numbers

  • •EIKN is the larger company ($409M vs $404M market cap).

Metrics side by side

Valuation

MetricAVIREIKN
P/B ratio1.980.88

Profitability

MetricAVIREIKN
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-80.96%-69.06%
ROIC-89.93%-46.16%

Growth (annualized)

MetricAVIREIKN
Total return CAGR (5Y)-34.44%N/A

Go deeper

Full AVIR analysisFull EIKN analysisInteractive comparison tool

Dig into the metrics

Atea Pharmaceuticals ROEEikon Therapeutics, Inc. Common Stock ROEAtea Pharmaceuticals operating marginEikon Therapeutics, Inc. Common Stock operating marginAtea Pharmaceuticals revenue growthEikon Therapeutics, Inc. Common Stock revenue growthAtea Pharmaceuticals free cash flowEikon Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.